[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363687-105":59,"doc-detail-363687-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-irf1-trim21-axis-enhances-anti-tumor-immunity-by-promoting-ubiquitin-mediated-degradation-of-fgl1-in-non-small-cell-lung-cancer","Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer","","Immunotherapy is widely used as a first-line treatment for advanced non-small cell lung cancer (NSCLC), yet more than half of patients do not benefit due to tumor heterogeneity and a complex tumor immune microenvironment. Targeting the immune checkpoint ligand FGL1, the TRIM21 E3 ubiquitin ligase drives proteasomal degradation, while IRF1 regulates TRIM21 transcription. Artemisinin enhances the IRF1–TRIM21 axis, promotes FGL1 degradation, and improves anti-tumor efficacy in combination with anti–PD-1 therapy. A higher FGL1/TRIM21 protein ratio correlates with poor prognosis in NSCLC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-irf1-trim21-axis-enhances-anti-tumor-immunity-by-promoting-ubiquitin-mediated-degradation-of-fgl1-in-non-small-cell-lung-cancer/363687/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-irf1-trim21-axis-enhances-anti-tumor-immunity-by-promoting-ubiquitin-mediated-degradation-of-fgl1-in-non-small-cell-lung-cancer/363687.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do many advanced NSCLC patients fail to benefit from immunotherapy?","Question",{"text":112,"@type":113},"More than half of patients fail to respond due to tumor heterogeneity and a complex tumor immune microenvironment that promotes immunotherapy resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does TRIM21 play in regulating anti-tumor immunity?",{"text":117,"@type":113},"TRIM21 targets the immune checkpoint ligand FGL1 for ubiquitin-mediated proteasomal degradation, enhancing cytotoxic T lymphocyte anti-tumor activity.",{"name":119,"@type":110,"acceptedAnswer":120},"How does artemisinin affect the IRF1–TRIM21 axis and treatment efficacy?",{"text":121,"@type":113},"Artemisinin upregulates IRF1, which increases TRIM21 transcription and promotes FGL1 degradation; combined with anti–PD-1 therapy, it enhances immunotherapeutic efficacy in FGL1-high tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363687,1790167239,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-026-10070-w](https://doi.org/10.1038/s42003-026-10070-w) |  |  |\n| Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediateddegradationofFGL1in non-small cell lung cancer\u003Cbr> Check for updates |  |  |\n| Yuchen Zhang1,5, Pingjing Zhou1,5, Yifan Guo1,2,5, Hongyu Zhang1, Guangyin Zhao1,2, Jun Yin1, Di Ge 1\u003Cbr>,\u003Cbr>Ronghua Liu3 , Jie Gu 1  & Chunyi Zhang 4  |  |  |\n| Immunotherapy has emerged as a ﬁrst-line treatment for patients with advanced non-small cell lung cancer (NSCLC), but over half of patients fail to beneﬁt, largely due to tumor heterogeneity and a complex tumor microenvironment. Here, we demonstrate that ﬁbrinogen-like protein 1 (FGL1), a recently identiﬁed immune checkpoint ligand, is targeted by tripartite motif-containing protein 21 (TRIM21) for proteasomal degradation, thereby enhancing the anti-tumor activity of cytotoxic T lymphocytes (CTLs) . We further show that interferon regulatory factor 1 (IRF1) regulates TRIM21 transcription. Artemisinin upregulates the IRF1-TRIM21 axis, promoting FGL1 degradation. In high FGL1 expressed tumors, artemisinin in combination with anti-programmed cell death protein 1 (antiPD-1) therapy enhances immunotherapeutic efﬁcacy. Clinically, an elevated FGL1/TRIM21 protein ratio is associated with poor prognosis in NSCLC. Collectively, these ﬁndings elucidate a posttranslational regulatory mechanism of FGL1 in tumor progression and support the development of a rational combination immunotherapy strategy for NSCLC treatment. |  |  |\n| The tumor immune microenvironment (TIME) comprises a complex network of immune cells and cytokines that collectively modulate antitumor responses1. Tumor cells evade immune surveillance by activating inhibitory immune checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), on cytotoxic T lymphocytes (CTLs), thereby contributing to immunotherapy resistance2,3. Although immunotherapy has become the ﬁrst-line treatment for patients with advanced non-small cell lung cancer (NSCLC)4, its efﬁcacy remains limited, with over halfofpatients failing to derive clinical beneﬁt, largely due to tumor heterogeneity and the intricate regulatory landscape ofthe TIME5. Consequently, elucidating the mechanisms underlying inhibitory immune checkpoints and their ligands is essential for overcoming resistance to immunotherapeutic interventions.\u003Cbr>Fibrinogen-like protein 1 (FGL1), the principal ligand of lymphocyte activation gene 3 (LAG-3), suppresses T-cell activation through its interaction with LAG-3. Inhibition of the LAG-3/FGL1 axis reactivates T-cell | function and enhances anti-tumor immunity6–8. Although FGL1 is predominantly secreted by the liver under physiological conditions, it is aberrantly overexpressed in several solid tumors, including NSCLC, melanoma, and colorectal cancer, where its elevated expression is associated with poor prognosis and reduced responsiveness to immunotherapy in lung cancer7,9, 10. FGL1 undergoes acetylation and ubiquitination, and activating its ubiquitination degradation pathway could improve NSCLC immunotherapy efﬁcacy11. However, the mechanisms regulating FGL1 protein stability in tumor cells remain incompletely deﬁned, highlighting the need to identify additional regulatory factors.\u003Cbr>Tripartite motif-containing protein 21 (TRIM21) is an intracellular E3 ubiquitin ligase initially identiﬁedasan autoantibody target in autoimmune disorders12. Widely expressed across tissues, TRIM21 has been primarily studied for its immunomodulatory role in viral infections and inﬂammatory responses13. Emerging evidence also implicates TRIM21 in tumorigenesis14, including modulating lipid metabolism in renal cell carcinoma15, inhibiting |  |\n\n1Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. 2Department of Thorac","cbCaifzH2pp1wAJN","https://ap.wps.com/l/cbCaifzH2pp1wAJN","pdf",11138229,16,"English","# Background\n## FGL1 and immune checkpoint signaling in NSCLC\n## TRIM21 as an E3 ubiquitin ligase\n## IRF1 regulation and tumor immunity","[{\"question\":\"Why do many advanced NSCLC patients fail to benefit from immunotherapy?\",\"answer\":\"More than half of patients fail to respond due to tumor heterogeneity and a complex tumor immune microenvironment that promotes immunotherapy resistance.\"},{\"question\":\"What role does TRIM21 play in regulating anti-tumor immunity?\",\"answer\":\"TRIM21 targets the immune checkpoint ligand FGL1 for ubiquitin-mediated proteasomal degradation, enhancing cytotoxic T lymphocyte anti-tumor activity.\"},{\"question\":\"How does artemisinin affect the IRF1–TRIM21 axis and treatment efficacy?\",\"answer\":\"Artemisinin upregulates IRF1, which increases TRIM21 transcription and promotes FGL1 degradation; combined with anti–PD-1 therapy, it enhances immunotherapeutic efficacy in FGL1-high tumors.\"}]","Targeting IRF1-TRIM21 axis enhances anti-tumor immunity by promoting ubiquitin-mediated degradation of FGL1 in non-small cell lung cancer | PDF",1790152686,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ccbf176c067e40db9a1bac530bab0835.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0f7e436e0f96fef3e4453d885a1a535.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0e321caf00ee37b2689c1ec86f71988.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1793bd6a500b3eda4ba01e5f019f7758.webp",980,1301]